Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Azoospermia Workup & Micro-TESE

Obstructive vs non-obstructive azoospermia; microdissection testicular sperm extraction

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Surgical procedure (regulated as medical practice)

Reference only. Not medical advice.

What can go wrong

Micro-TESE risks include hematoma, transient testosterone decline, and devascularization; not all NOA men have retrievable sperm. AZFa or AZFb complete deletions predict near-zero retrieval and should be tested first to avoid futile surgery. Klinefelter and other causes carry genetic transmission considerations requiring counseling and often preimplantation testing.

This is something to take to a clinician. The Atlas can tell you what is known about azoospermia workup & micro-tese in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Azoospermia (no sperm in the ejaculate, confirmed after centrifugation on two samples) affects ~1% of men and up to ~10-15% of infertile men. The pivotal fork is obstructive (production intact, outflow blocked) versus non-obstructive (impaired or absent production). Microdissection testicular sperm extraction (micro-TESE), refined by Peter Schlegel, uses an operating microscope to find rare pockets of spermatogenesis in non-obstructive cases, with sperm-retrieval rates substantially higher than blind biopsy.

No sperm in the ejaculate is not the end of the line - it's the start of a workup.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Distinguishing obstructive from non-obstructive azoospermia
  • Sperm retrieval for ICSI in non-obstructive azoospermia
  • Genetic counseling (CFTR/CBAVD, Y-microdeletions, Klinefelter)
  • Identifying reversible/treatable causes (post-vasectomy, hypogonadotropic hypogonadism)

How it works

Workup combines history (cryptorchidism, chemo, mumps orchitis, vasectomy), exam (testis volume, vas presence), hormones (high FSH with small testes suggests primary spermatogenic failure; normal FSH with normal testes and absent vas suggests obstruction/CBAVD), and genetics. In micro-TESE, the testis is opened and the surgeon scans seminiferous tubules at high magnification, selecting larger, opaque tubules more likely to contain sperm - sparing tissue and vasculature compared to multiple blind biopsies.

What people get wrong

  • Often saidNo sperm in the semen means biological fatherhood is impossible

    ActuallyIn many non-obstructive cases, micro-TESE recovers usable sperm for ICSI; obstructive cases nearly always yield sperm. Azoospermia is a workup trigger, not a verdict.

  • Often saidA single semen sample showing no sperm confirms azoospermia

    ActuallyDiagnosis requires at least two centrifuged samples; transient zero counts occur.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

Conventional TESE and TESA gave way to microdissection TESE after Peter Schlegel's 1999 description at Weill Cornell, which became the reference technique for non-obstructive azoospermia. Parallel advances in Y-microdeletion testing (AZFa/b/c regions) refined patient selection and prognosis.

  1. 1990sY-chromosome AZF microdeletions characterized
  2. 1999Schlegel describes microdissection TESE
  3. 2000sMicro-TESE-ICSI becomes standard of care for NOA at expert centers

Set against the alternatives

Obstructive azoospermia is highly treatable: reconstruction (vasovasostomy/vasoepididymostomy) or simple aspiration (PESA/MESA/TESA) yields abundant sperm. Non-obstructive azoospermia is the hard case, where micro-TESE outperforms conventional TESE and TESA on retrieval rate while preserving more testicular tissue.

What we do not know

  • Can imaging, biomarkers, or AI predict which NOA testes harbor sperm before surgery?
  • Do hormonal optimization regimens before micro-TESE meaningfully raise retrieval?
  • Will spermatogonial stem-cell or in-vitro spermatogenesis ever rescue Sertoli-cell-only patients?

At a glance

Azoospermia in infertile men
~10-15%
Micro-TESE sperm retrieval (NOA)
~40-60% in major series
Key labs
FSH, testosterone; karyotype and Y-microdeletion testing
Klinefelter (47,XXY)
a leading genetic cause of NOA, yet sperm often retrievable

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Azoospermia Workup & Micro-TESE. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Schlegel - microdissection TESE technique1999

    Introduced microsurgical TESE, improving retrieval and reducing tissue loss vs conventional TESE

  • Schlegel and colleagues - NOA micro-TESE outcome series2000s-2010s

    Reported sperm retrieval in roughly half of non-obstructive azoospermia cases, with ICSI live births from retrieved testicular sperm

  • Y-chromosome microdeletion analyses1990s-2000s

    AZFa/AZFb complete deletions predict failed retrieval; AZFc deletions often retrievable but transmissible to sons